US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aardvark Therapeutics

10.33

+0.41004.13%

Volume:193.44K

Turnover:1.99M

Market Cap:224.13M

PE:-15.94

High:10.94

Open:9.97

Low:9.92

Close:9.92

52wk High:19.58

52wk Low:4.88

Shares:21.70M

Float Shares:5.89M

Volume Ratio:1.97

T/O Rate:3.29%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.6480

EPS(LYR):-0.7400

ROE:-33.09%

ROA:-21.76%

PB:1.64

PE(LYR):-13.96

Loading ...

Overview Company News Filings

Aardvark Therapeutics Is Maintained at Outperform by RBC Capital

Cantor Fitzgerald Reaffirms Their Buy Rating on Aardvark Therapeutics, Inc. (AARD)

BTIG Remains a Buy on Aardvark Therapeutics, Inc. (AARD)

RBC Cuts Price Target on Aardvark Therapeutics to $18 From $19, Keeps Outperform, Speculative Risk

MT Newswires Live

Aardvark Therapeutics Q3 EPS $(0.75) Beats $(0.80) Estimate

Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

This Aardvark Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday

Benzinga_recent_news

Aardvark Therapeutics Inc : Btig Initiates Coverage With Buy Rating; Price Target $26

THOMSON REUTERS

Aardvark Therapeutics Initiated at Buy by BTIG

Aardvark Therapeutics Showcases Obesity Research at ObesityWeek

Aardvark Therapeutics Showcases Metabolic Obesity Pipeline at ObesityWeek

Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Aardvark Therapeutics to Present at Stifel Healthcare Conference

Aardvark Therapeutics Advances PWS Treatment with ARD-101 Study

Aardvark Therapeutics Unveils Positive Obesity Drug Data at ObesityWeek 2025

Aardvark Therapeutics Aligns with FDA on Trial Amendment

Aardvark Therapeutics Inc - Trial Eligibility Age Changed From 13 to 10 Years

THOMSON REUTERS

Aardvark Therapeutics Inc - Topline Data Readout for Trial Expected in Q3 2026

THOMSON REUTERS

Aardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi Syndrome

Aardvark Therapeutics Initiated at Buy by Jones Trading

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/AARD/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AARD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AARD\",,,,,undefined,":{"symbol":"AARD","market":"US","secType":"STK","nameCN":"Aardvark Therapeutics","latestPrice":10.33,"timestamp":1763411608941,"preClose":9.92,"halted":0,"volume":193439,"delay":0,"floatShares":5888000,"shares":21696893,"eps":-0.648,"marketStatus":"Trading","change":0.41,"latestTime":"11-17 15:34:18 EST","open":9.97,"high":10.94,"low":9.9201,"amount":1994161.490366,"amplitude":0.102812,"askPrice":10.37,"askSize":200,"bidPrice":10.27,"bidSize":500,"shortable":0,"etf":0,"ttmEps":-0.648,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1763413200000},"marketStatusCode":2,"adr":0,"listingDate":1739509200000,"exchange":"NASDAQ","adjPreClose":9.92,"postHourTrading":{"tag":"盘后","latestPrice":9.92,"preClose":9.92,"latestTime":"19:03 EST","volume":195,"amount":1940.82,"timestamp":1763165020843},"volumeRatio":1.973161},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AARD\",,,,,undefined,":{"symbol":"AARD","floatShares":5888000,"roa":"-21.76%","roe":"-33.09%","lyrEps":-0.74,"volumeRatio":1.973161,"shares":21696893,"dividePrice":0,"high":10.94,"amplitude":0.102812,"preClose":9.92,"low":9.9201,"week52Low":4.88,"pbRate":"1.64","week52High":19.58,"institutionHeld":0,"latestPrice":10.33,"committee":0.428571,"eps":-0.648,"divideRate":0,"volume":193439,"delay":0,"ttmEps":-0.648,"open":9.97,"prevYearClose":16,"prevWeekClose":9.92,"prevMonthClose":10.69,"prevQuarterClose":13.29,"fiveDayClose":10.44,"twentyDayClose":12.28,"sixtyDayClose":9.77},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AARD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-13","symbol":"AARD","fiscalQuarterEnding":"2025/09","expectedEps":-0.82,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-0.75},{"market":"US","date":"2025-08-13","symbol":"AARD","fiscalQuarterEnding":"2025/06","expectedEps":-0.52,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"post","actualEps":-0.66},{"market":"US","date":"2025-05-14","symbol":"AARD","fiscalQuarterEnding":"2025/03","expectedEps":-0.7,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"post","actualEps":-0.71},{"market":"US","date":"2025-03-31","symbol":"AARD","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AARD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AARD\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AARD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AARD","date":"2025-11-14","current":-15.910494,"percent":0.819149,"low":-51.17654,"twenty":-11.527382,"median":-8.978494,"eighty":-6.599437,"high":-4.61321,"avg":-12.415283,"sd":9.740001,"marketCap":236457733},"quantilePoints":[{"date":"2025-02-21","current":-51.17654,"twenty":-46.993414,"median":-42.216938,"eighty":-39.920668,"marketCap":368880503},{"date":"2025-02-28","current":-39.75453,"twenty":-42.139802,"median":-40.229211,"eighty":-39.232381,"marketCap":286550651},{"date":"2025-03-07","current":-28.243517,"twenty":-40.603022,"median":-39.176012,"eighty":-36.900511,"marketCap":203579269},{"date":"2025-03-14","current":-31.091602,"twenty":-40.336014,"median":-37.766803,"eighty":-30.723725,"marketCap":224108270},{"date":"2025-03-21","current":-27.23482,"twenty":-39.944402,"median":-34.681377,"eighty":-29.198812,"marketCap":196308580},{"date":"2025-03-28","current":-26.404128,"twenty":-39.576524,"median":-30.913597,"eighty":-27.946841,"marketCap":190320955},{"date":"2025-04-04","current":-9.026143,"twenty":-39.119644,"median":-30.068072,"eighty":-27.341623,"marketCap":185830236},{"date":"2025-04-11","current":-7.397773,"twenty":-38.751766,"median":-29.400552,"eighty":-17.252871,"marketCap":152305358},{"date":"2025-04-17","current":-7.977371,"twenty":-38.300819,"median":-28.45119,"eighty":-8.603741,"marketCap":164238114},{"date":"2025-04-25","current":-8.66235,"twenty":-37.766803,"median":-27.946841,"eighty":-8.371497,"marketCap":178340462},{"date":"2025-05-02","current":-11.939711,"twenty":-36.900511,"median":-27.412825,"eighty":-8.371497,"marketCap":245814773},{"date":"2025-05-09","current":-11.307423,"twenty":-34.865316,"median":-26.68597,"eighty":-8.46634,"marketCap":232797221},{"date":"2025-05-16","current":-7.114571,"twenty":-32.693651,"median":-13.552046,"eighty":-8.46634,"marketCap":197215912},{"date":"2025-05-23","current":-7.834638,"twenty":-31.0204,"median":-11.823792,"eighty":-8.360959,"marketCap":217176159},{"date":"2025-05-30","current":-8.061615,"twenty":-30.818661,"median":-11.433881,"eighty":-8.172533,"marketCap":223467976},{"date":"2025-06-06","current":-9.353039,"twenty":-30.367714,"median":-11.107198,"eighty":-8.178795,"marketCap":259266244},{"date":"2025-06-13","current":-8.656453,"twenty":-30.076972,"median":-10.833207,"eighty":-8.210998,"marketCap":239956875},{"date":"2025-06-20","current":-9.454788,"twenty":-30.053238,"median":-10.188135,"eighty":-8.218152,"marketCap":262086713},{"date":"2025-06-27","current":-10.84796,"twenty":-29.697227,"median":-10.664596,"eighty":-8.356744,"marketCap":300705451},{"date":"2025-07-03","current":-10.894921,"twenty":-29.459887,"median":-10.613156,"eighty":-8.365174,"marketCap":302007206},{"date":"2025-07-11","current":-9.861782,"twenty":-29.308323,"median":-10.597502,"eighty":-8.375712,"marketCap":273368592},{"date":"2025-07-18","current":-9.360866,"twenty":-28.618005,"median":-10.433139,"eighty":-8.40036,"marketCap":259483203},{"date":"2025-07-25","current":-10.542714,"twenty":-28.285052,"median":-10.45662,"eighty":-8.474871,"marketCap":292244042},{"date":"2025-08-01","current":-9.4,"twenty":-28.006176,"median":-10.433139,"eighty":-8.577715,"marketCap":260567999},{"date":"2025-08-08","current":-9.368693,"twenty":-27.946841,"median":-10.061366,"eighty":-8.607418,"marketCap":259700162},{"date":"2025-08-15","current":-6.668132,"twenty":-27.567096,"median":-9.861782,"eighty":-8.474871,"marketCap":244307015},{"date":"2025-08-22","current":-5.762071,"twenty":-27.424692,"median":-9.803081,"eighty":-8.329026,"marketCap":211110768},{"date":"2025-08-29","current":-5.027748,"twenty":-27.270421,"median":-9.525229,"eighty":-8.145134,"marketCap":184206621},{"date":"2025-09-05","current":-5.027748,"twenty":-27.074615,"median":-9.478268,"eighty":-8.014507,"marketCap":184206621},{"date":"2025-09-12","current":-4.61321,"twenty":-26.629602,"median":-9.396086,"eighty":-7.797069,"marketCap":169018796},{"date":"2025-09-19","current":-6.685898,"twenty":-23.929853,"median":-9.368693,"eighty":-7.515801,"marketCap":244957921},{"date":"2025-09-26","current":-7.503129,"twenty":-17.043362,"median":-9.298251,"eighty":-7.308831,"marketCap":274899634},{"date":"2025-10-03","current":-9.102059,"twenty":-12.821851,"median":-9.210333,"eighty":-7.389343,"marketCap":333481245},{"date":"2025-10-10","current":-9.824539,"twenty":-12.161077,"median":-9.298251,"eighty":-7.460987,"marketCap":359951454},{"date":"2025-10-17","current":-7.876213,"twenty":-12.040618,"median":-9.212156,"eighty":-7.503145,"marketCap":288568676},{"date":"2025-10-24","current":-6.425331,"twenty":-11.978881,"median":-9.149542,"eighty":-7.334887,"marketCap":235411289},{"date":"2025-10-31","current":-6.194375,"twenty":-11.800608,"median":-9.102059,"eighty":-7.096882,"marketCap":226949500},{"date":"2025-11-07","current":-5.844979,"twenty":-11.619352,"median":-9.083015,"eighty":-6.739195,"marketCap":214148333},{"date":"2025-11-14","current":-6.453893,"twenty":-11.527382,"median":-8.978494,"eighty":-6.599437,"marketCap":236457733}],"updateTime":1763411658908},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AARD\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2583150015","title":"Aardvark Therapeutics Is Maintained at Outperform by RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2583150015","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583150015?lang=en_us&edition=fundamental","pubTime":"2025-11-14 23:47","pubTimestamp":1763135220,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AARD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 14, 2025 10:47 ET (15:47 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"gpt_icon":0},{"id":"2583509025","title":"Cantor Fitzgerald Reaffirms Their Buy Rating on Aardvark Therapeutics, Inc. (AARD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583509025","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583509025?lang=en_us&edition=fundamental","pubTime":"2025-11-14 21:36","pubTimestamp":1763127381,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald analyst Joshua Schimmer reiterated a Buy rating on Aardvark Therapeutics, Inc. yesterday and set a price target of $50.00. The co...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cantor-fitzgerald-reaffirms-their-buy-rating-on-aardvark-therapeutics-inc-aard-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cantor-fitzgerald-reaffirms-their-buy-rating-on-aardvark-therapeutics-inc-aard-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AARD"],"gpt_icon":0},{"id":"2583054635","title":"BTIG Remains a Buy on Aardvark Therapeutics, Inc. (AARD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583054635","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583054635?lang=en_us&edition=fundamental","pubTime":"2025-11-14 20:35","pubTimestamp":1763123739,"startTime":"0","endTime":"0","summary":"BTIG analyst Jeet Mukherjee reiterated a Buy rating on Aardvark Therapeutics, Inc. today and set a price target of $26.00. Mukherjee covers the Hea...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/btig-remains-a-buy-on-aardvark-therapeutics-inc-aard-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/btig-remains-a-buy-on-aardvark-therapeutics-inc-aard-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AARD"],"gpt_icon":0},{"id":"2583508647","title":"RBC Cuts Price Target on Aardvark Therapeutics to $18 From $19, Keeps Outperform, Speculative Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2583508647","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583508647?lang=en_us&edition=fundamental","pubTime":"2025-11-14 19:51","pubTimestamp":1763121085,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics (AARD) has an average rating of buy and mean price target of $30.63, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from maj","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AARD"],"gpt_icon":0},{"id":"2583512264","title":"Aardvark Therapeutics Q3 EPS $(0.75) Beats $(0.80) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2583512264","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583512264?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:32","pubTimestamp":1763069550,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics (NASDAQ:AARD) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate of $(0.80) by 6.72 percent. This is a 28.57 percent increase over losses of $(1.05) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48851385/aardvark-therapeutics-q3-eps-0-75-beats-0-80-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Aardvark Therapeutics Q3 EPS $(0.75) Beats $(0.80) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"gpt_icon":0},{"id":"2582390237","title":"Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582390237","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582390237?lang=en_us&edition=fundamental","pubTime":"2025-11-12 05:05","pubTimestamp":1762895100,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Nov.  11, 2025  (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutic","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/11/3185762/0/en/Aardvark-Therapeutics-Announces-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-C-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BSNM7G36.USD","PSQ","LU0310800965.SGD","LU0648001328.SGD","LU0130102774.USD","LU1201861249.SGD","LU0130517989.USD","AARD","LU1162221912.USD","LU0980610538.SGD","LU0320765646.SGD","LU0106831901.USD","BK4207","NQmain","BK4534","LU2125154778.USD","LU2462157665.USD","LU2360032135.SGD",".IXIC","BK4504","LU1267930227.SGD","LU0477156953.USD","LU1244550577.SGD","BK4559","LU0072461881.USD","NVIW.SI","QID","LU0128525689.USD","QLD","LU0170899867.USD","MNQmain","LU1791807156.HKD","LU1244550221.USD","LU2125154935.USD","LU0162691827.USD","LU2417539215.USD","BK4566","USJW.SI","TSYW.SI","USAW.SI","TQQQ","LU1244550494.USD","BK4585","LU1668664300.SGD","LU2236285917.USD","LU0098860793.USD","BK4588","LU0052756011.USD","SQQQ"],"gpt_icon":1},{"id":"2581835427","title":"This Aardvark Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=2581835427","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581835427?lang=en_us&edition=fundamental","pubTime":"2025-11-08 02:57","pubTimestamp":1762541820,"startTime":"0","endTime":"0","summary":"Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/07/Analyst-Woman-Working-With-Information-D.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/07/Analyst-Woman-Working-With-Information-D.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/analyst-stock-ratings/initiation/25/11/48730325/this-aardvark-therapeutics-analyst-begins-coverage-on-a-bullish-note-here-are-top-3-initiations-for-friday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/initiation/25/11/48730325/this-aardvark-therapeutics-analyst-begins-coverage-on-a-bullish-note-here-are-top-3-initiations-for-friday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["AARD","BK4112"],"gpt_icon":0},{"id":"2581888526","title":"Aardvark Therapeutics Inc : Btig Initiates Coverage With Buy Rating; Price Target $26","url":"https://stock-news.laohu8.com/highlight/detail?id=2581888526","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581888526?lang=en_us&edition=fundamental","pubTime":"2025-11-07 20:57","pubTimestamp":1762520264,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nFWN3WJ214:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AARD"],"gpt_icon":0},{"id":"2581147004","title":"Aardvark Therapeutics Initiated at Buy by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2581147004","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581147004?lang=en_us&edition=fundamental","pubTime":"2025-11-07 19:40","pubTimestamp":1762515600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AARD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 07, 2025 06:40 ET (11:40 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"gpt_icon":0},{"id":"2581798590","title":"Aardvark Therapeutics Showcases Obesity Research at ObesityWeek","url":"https://stock-news.laohu8.com/highlight/detail?id=2581798590","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581798590?lang=en_us&edition=fundamental","pubTime":"2025-11-05 06:17","pubTimestamp":1762294654,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics, Inc. ( ($AARD) ) has issued an announcement. On November 4, 2025, Aardvark Therapeutics presented research at the ObesityWee...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aardvark-therapeutics-showcases-obesity-research-at-obesityweek?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aardvark-therapeutics-showcases-obesity-research-at-obesityweek?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AARD"],"gpt_icon":0},{"id":"2581475463","title":"Aardvark Therapeutics Showcases Metabolic Obesity Pipeline at ObesityWeek","url":"https://stock-news.laohu8.com/highlight/detail?id=2581475463","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581475463?lang=en_us&edition=fundamental","pubTime":"2025-11-05 01:00","pubTimestamp":1762275653,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics Inc. will host an investor webinar on November 5, 2025, to review data on its ARD-101 and ARD-201 metabolic obesity programs, as well as results presented at ObesityWeek 2025. The event will feature discussions with key opinion leaders and include new preclinical findings highlighting the potential of ARD-201 in enhanced glucose control, preservation of lean mass, and weight management.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aardvark Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on November 04, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDLKJW4C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","BK4588","LU2095319765.USD","AARD","IE00BKPKM429.USD","BK4112","IE00BGHQF748.EUR","LU0314104364.USD","LU2210149790.SGD","LU2210150020.SGD","BK4585","IE00B3QW5Z07.USD","NDAQ"],"gpt_icon":0},{"id":"2580224420","title":"Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2580224420","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580224420?lang=en_us&edition=fundamental","pubTime":"2025-11-04 06:55","pubTimestamp":1762210500,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Nov.  03, 2025  (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutic","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/03/3179909/0/en/Aardvark-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-C-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","LU1162221912.USD","TQQQ","IE00BSNM7G36.USD","LU2360032135.SGD","USAW.SI","LU2456880835.USD","LU2125154935.USD","LU0128525689.USD","BK4559","BK4588","MNQmain","LU0648001328.SGD","LU0130517989.USD","LU0052756011.USD","BK4504","LU2125154778.USD","LU0980610538.SGD","LU2417539215.USD","QLD","AARD","SQQQ","BK4534","NQmain","LU1244550221.USD",".IXIC","LU1244550577.SGD","QID","LU1267930227.SGD","LU1668664300.SGD","LU0072461881.USD","PSQ","LU0477156953.USD","LU0106831901.USD","LU1201861249.SGD","NVIW.SI","LU0162691827.USD","USJW.SI","LU0170899867.USD","LU2236285917.USD","LU1244550494.USD","LU0098860793.USD","LU0310800965.SGD","BK4207","LU0320765646.SGD","LU1366192091.USD","TSYW.SI","LU2462157665.USD","LU0130102774.USD"],"gpt_icon":1},{"id":"2580213684","title":"Aardvark Therapeutics to Present at Stifel Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2580213684","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580213684?lang=en_us&edition=fundamental","pubTime":"2025-11-03 21:01","pubTimestamp":1762174888,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics Inc. will present at the Stifel 2025 Healthcare Conference in New York on November 11 at 4:40 p.m. ET. The company, which develops novel small-molecule therapeutics for metabolic diseases, will also participate in the TD Cowen Treatment Advancements in Obesity & Related Disorders Summit virtually on November 24 at 3:00 p.m. ET.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aardvark Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on November 03, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL7KPYyV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","IE00BGHQF748.EUR","LU2210150020.SGD","LU0314104364.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","BK4127","IE00B3QW5Z07.USD","LU2095319765.USD","BK4585","AARD","SF","NDAQ","LU2210149790.SGD","BK4588"],"gpt_icon":0},{"id":"2578067674","title":"Aardvark Therapeutics Advances PWS Treatment with ARD-101 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2578067674","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578067674?lang=en_us&edition=fundamental","pubTime":"2025-10-28 06:19","pubTimestamp":1761603554,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics, Inc. (($AARD)) announced an update on their ongoing clinical study. Study Overview: Aardvark Therapeutics, Inc. is conductin...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aardvark-therapeutics-advances-pws-treatment-with-ard-101-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aardvark-therapeutics-advances-pws-treatment-with-ard-101-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AARD","PWS","ARD"],"gpt_icon":0},{"id":"2577936183","title":"Aardvark Therapeutics Unveils Positive Obesity Drug Data at ObesityWeek 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2577936183","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577936183?lang=en_us&edition=fundamental","pubTime":"2025-10-22 20:00","pubTimestamp":1761134427,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics Inc. announced that it will present new data from its pipeline programs at ObesityWeek 2025, scheduled for November 4-7, 2025, in Atlanta, Georgia. The company will share poster presentations on its investigational compounds, including ARD-101, a TAS2R pan-agonist evaluated for its effects on weight gain in mice and hunger reduction in adults with obesity, and WE-868, an isoflavonoid modulator of oxidative metabolism with therapeutic potential in obesity and diabetes. The data will be presented by Chief Scientific Officer Timothy Kieffer, Ph.D., and Chief Executive Officer Tien Lee, M.D., on November 4, 2025. Additionally, Aardvark will host an investor webinar on November 5, 2025, to discuss the presented data and provide updates on ARD-101's development in Prader-Willi Syndrome. The company will make an archived recording of the webinar available on its website for approximately one month after the event.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251022:nNDLbLx9NK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","NDAQ","LU2210150020.SGD","IE00BKPKM429.USD","AARD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","BK4588","IE00B3QW5Z07.USD","LU2210149790.SGD","LU2095319765.USD","BK4585","BK4112"],"gpt_icon":0},{"id":"2574155155","title":"Aardvark Therapeutics Aligns with FDA on Trial Amendment","url":"https://stock-news.laohu8.com/highlight/detail?id=2574155155","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574155155?lang=en_us&edition=fundamental","pubTime":"2025-10-09 18:36","pubTimestamp":1760006206,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics, Inc. ( ($AARD) ) has shared an announcement. On October 8, 2025, Aardvark Therapeutics announced an alignment with the U.S. ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aardvark-therapeutics-aligns-with-fda-on-trial-amendment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aardvark-therapeutics-aligns-with-fda-on-trial-amendment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AARD"],"gpt_icon":0},{"id":"2573928147","title":"Aardvark Therapeutics Inc - Trial Eligibility Age Changed From 13 to 10 Years","url":"https://stock-news.laohu8.com/highlight/detail?id=2573928147","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573928147?lang=en_us&edition=fundamental","pubTime":"2025-10-08 20:00","pubTimestamp":1759924801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nTUA92WXL6:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AARD"],"gpt_icon":0},{"id":"2573140928","title":"Aardvark Therapeutics Inc - Topline Data Readout for Trial Expected in Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2573140928","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573140928?lang=en_us&edition=fundamental","pubTime":"2025-10-08 20:00","pubTimestamp":1759924801,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nTUA92WXL6:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AARD"],"gpt_icon":0},{"id":"2573928291","title":"Aardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2573928291","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573928291?lang=en_us&edition=fundamental","pubTime":"2025-10-08 20:00","pubTimestamp":1759924800,"startTime":"0","endTime":"0","summary":"Protocol Expansion to Ages 10+ Aligned with FDA Guidance, Broadening Patient PopulationSAN DIEGO, Oct.  08, 2025  (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/08/3163296/0/en/Aardvark-Therapeutics-Announces-FDA-Alignment-on-Protocol-Amendment-Expanding-Phase-3-HERO-Trial-Population-for-Prader-Willi-Syndrome.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0211328371.USD","BK4126","LU0310799852.SGD","HERO","LU1267930573.SGD","PWS","LU0029864427.USD","LU0029874061.USD","LU0128525929.USD","LU0310800379.SGD","LU0708994859.HKD","CCK","LU1803068623.USD","LU1267930490.SGD","LU1892829315.USD","LU0211327993.USD","AARD","LU0128526141.USD"],"gpt_icon":0},{"id":"2572533816","title":"Aardvark Therapeutics Initiated at Buy by Jones Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2572533816","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572533816?lang=en_us&edition=fundamental","pubTime":"2025-10-01 18:54","pubTimestamp":1759316040,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AARD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 01, 2025 06:54 ET (10:54 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":55,"code":"91000000","status":"200"}]}}